President Luiz Inácio Lula da Silva signed a law on July 20, 2026 [3], establishing a permanent national strategy to increase domestic production of medicines and vaccines.
The move aims to secure the sovereignty of Brazil's healthcare system by reducing its dependence on external suppliers for essential medical equipment and pharmaceuticals. By strengthening the national industrial complex, the government seeks to ensure that the Unified Health System (SUS) remains resilient against global supply chain disruptions.
The legislation officially institutes the National Health Strategy for the Economic-Industrial Complex of Health (ENSCEIS) [1]. While the ENSCEIS framework was originally created in 2023 [2], this new law transforms the initiative into a permanent state policy. The strategy incorporates elements from Bill PL 2.583/2020 [4] to solidify the legal basis for the industrial expansion.
Under the new rules, the Brazilian government will prioritize purchasing from domestic companies. To qualify for this preference, companies must maintain their headquarters, factories, and shareholding control within Brazil.
"This law represents a landmark for health sovereignty in Brazil," Lula said.
The administration intends to use the policy to stimulate scientific and technological innovation. By fostering a local ecosystem of strategic companies, the government hopes to lower the long-term costs of providing healthcare to the population through the SUS.
"From now on, public purchases will have preference for national companies that have a headquarters, factory, and shareholding control in Brazil," Lula said.
A spokesperson for the Ministry of Health said that the strategy will allow for a lower external dependency for the SUS [5]. The focus remains on expanding the capacity to produce not only medicines, but also vaccines and specialized medical equipment to safeguard public health.
“"This law represents a landmark for health sovereignty in Brazil."”
By transitioning ENSCEIS from a temporary initiative to a permanent law, Brazil is attempting to insulate its public health infrastructure from geopolitical volatility and price fluctuations in the global pharmaceutical market. The requirement for domestic shareholding control suggests a protectionist approach designed to prevent foreign firms from simply rebranding imported goods as local products to secure government contracts.
